Proteon Therapeutics (NASDAQ:PRTO) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.
This is a summary of current recommendations and price targets for Proteon Therapeutics and Gilead Sciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Proteon Therapeutics currently has a consensus target price of $3.00, suggesting a potential upside of 91.08%. Gilead Sciences has a consensus target price of $88.20, suggesting a potential upside of 17.94%. Given Proteon Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Proteon Therapeutics is more favorable than Gilead Sciences.
Valuation & Earnings
This table compares Proteon Therapeutics and Gilead Sciences’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Proteon Therapeutics||N/A||N/A||-$29.96 million||($2.13)||-0.74|
|Gilead Sciences||$26.11 billion||3.71||$4.63 billion||$8.56||8.74|
Gilead Sciences has higher revenue and earnings than Proteon Therapeutics. Proteon Therapeutics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.
Gilead Sciences pays an annual dividend of $2.28 per share and has a dividend yield of 3.0%. Proteon Therapeutics does not pay a dividend. Gilead Sciences pays out 26.6% of its earnings in the form of a dividend. Gilead Sciences has increased its dividend for 2 consecutive years.
Risk & Volatility
Proteon Therapeutics has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500.
Institutional & Insider Ownership
50.6% of Proteon Therapeutics shares are held by institutional investors. Comparatively, 78.0% of Gilead Sciences shares are held by institutional investors. 45.7% of Proteon Therapeutics shares are held by company insiders. Comparatively, 1.2% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Proteon Therapeutics and Gilead Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Gilead Sciences beats Proteon Therapeutics on 12 of the 17 factors compared between the two stocks.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to improve hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.
Gilead Sciences Company Profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen Sciences Ireland UC, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.